Sepideh Mirzaei
Overview
Explore the profile of Sepideh Mirzaei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
1917
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rismanchi H, Malek Mohammadi M, Mafi A, Khalilzadeh P, Farahani N, Mirzaei S, et al.
Clin Transl Oncol
. 2024 Dec;
PMID: 39623194
Cancer is one of the primary causes of human disease and death, with high morbidity and mortality rates. Chemotherapy, one of the most common therapeutic techniques, functions through a variety...
2.
Mirzaei S, Ahangari F, Faramarzi F, Khoshnazar S, Khormizi F, Aghagolzadeh M, et al.
Pathol Res Pract
. 2024 Nov;
264:155707.
PMID: 39536541
Glioma is a highly lethal brain cancer in humans. Despite advancements in treatment, the prognosis for patients remains unfavorable. Epigenetic factors, along with their interactions and non-coding RNAs (ncRNAs), are...
3.
Yildiz S, Entezari M, Paskeh M, Mirzaei S, Kalbasi A, Zabolian A, et al.
MedComm (2020)
. 2024 Jun;
5(7):e583.
PMID: 38919334
Nonviral vectors, such as liposomes, offer potential for targeted gene delivery in cancer therapy. Liposomes, composed of phospholipid vesicles, have demonstrated efficacy as nanocarriers for genetic tools, addressing the limitations...
4.
Entezari M, Tayari A, Paskeh M, Kheirabad S, Naeemi S, Taheriazam A, et al.
J Tradit Complement Med
. 2024 Mar;
14(2):121-134.
PMID: 38481552
Hematological cancers include leukemia, myeloma and lymphoma and up to 178.000 new cases are diagnosed with these tumors each year. Different kinds of treatment including radiotherapy, chemotherapy, immunotherapy and stem...
5.
Gholami M, Rassouli A, Mirzaei S, Hashemi F
J Adv Vet Anim Res
. 2024 Feb;
10(4):620-629.
PMID: 38370882
This study conducted a literature review to investigate the immunomodulatory effect of levamisole in both humans and farm animals. The following procedure was followed for database searching: PubMed, Google Scholar,...
6.
Mirzaei S, Paskeh M, Moghadam F, Entezari M, Koohpar Z, Hejazi E, et al.
J Cell Commun Signal
. 2023 Nov;
17(4):1181-1202.
PMID: 38019354
The treatment of cancer patients has been prohibited by chemoresistance. Doxorubicin (DOX) is an anti-tumor compound disrupting proliferation and triggering cell cycle arrest via inhibiting activity of topoisomerase I and...
7.
Rashidi M, Bazi A, Ahmadzadeh A, Romeo O, Rezaei-Matehkolaei A, Abastabar M, et al.
J Appl Microbiol
. 2023 Sep;
134(9).
PMID: 37669891
Aims: Umbelliprenin has shown promising biological activities, including immunoregulatory, anti-inflammatory, and anti-cancer effects. The present study investigated the growth inhibitory and apoptotic effects of umbelliprenin against Candida albicans in a...
8.
Shakiba E, Bazi A, Ghasemi H, Eshaghi-Gorji R, Mehdipour S, Nikfar B, et al.
J Cell Mol Med
. 2023 Aug;
27(18):2756-2769.
PMID: 37581480
Considering the unfavourable response of breast cancer (BC) to treatment, we assessed the therapeutic potential hesperidin in mice bearing 4T1 BC tumours. Anti-tumour effects were assessed by measuring pathologic complete...
9.
Khosravi F, Hojati V, Mirzaei S, Hashemi M, Entezari M
Brain Res Bull
. 2023 Aug;
201:110726.
PMID: 37543296
Background: Young onset Parkinson disease (YOPD) accounts for about 10% of PD patients, with the onset of symptoms between the ages of 21 and 40. At this age, the probability...
10.
Mirzaei S, Ranjbar B, Tackallou S
Pathol Res Pract
. 2023 Aug;
248:154708.
PMID: 37536019
The glycolysis is a common characteristic of cancer and it is responsible for providing enough energy to ensure growth. The glycolysis suppression is beneficial in tumor growth reduction. The stimulation/inhibition...